Research programme: ubiquitin protein ligase inhibitors - BPG Bio
Latest Information Update: 24 Apr 2026
At a glance
- Originator BPG Bio
- Class Antineoplastics
- Mechanism of Action Ubiquitin protein ligase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 02 Feb 2026 Early research in Cancer in USA (unspecified route) before February 2026 (BPG Bio pipeline, February 2026)